State Board of Administration of Florida Retirement System maintained its position in Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 75,246 shares of the biopharmaceutical company’s stock at the end of the second quarter. State Board of Administration of Florida Retirement System owned approximately 0.06% of Achillion Pharmaceuticals worth $587,000 at the end of the most recent quarter.
Several other institutional investors have also added to or reduced their stakes in the company. Schonfeld Strategic Advisors LLC acquired a new position in Achillion Pharmaceuticals during the first quarter worth approximately $101,000. Fox Run Management L.L.C. acquired a new position in Achillion Pharmaceuticals during the second quarter worth approximately $105,000. Legal & General Group Plc increased its position in Achillion Pharmaceuticals by 15.7% in the first quarter. Legal & General Group Plc now owns 18,010 shares of the biopharmaceutical company’s stock worth $140,000 after buying an additional 2,443 shares during the last quarter. Bourgeon Capital Management LLC increased its position in Achillion Pharmaceuticals by 41.9% in the second quarter. Bourgeon Capital Management LLC now owns 30,500 shares of the biopharmaceutical company’s stock worth $238,000 after buying an additional 9,000 shares during the last quarter. Finally, HBK Investments L P acquired a new position in Achillion Pharmaceuticals during the first quarter worth approximately $455,000. 79.43% of the stock is owned by institutional investors.
Shares of Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) traded down 1.6555% during trading on Tuesday, hitting $7.9069. 492,826 shares of the company’s stock were exchanged. The stock has a market cap of $1.08 billion, a PE ratio of 161.3653 and a beta of 2.10. Achillion Pharmaceuticals Inc. has a 1-year low of $5.57 and a 1-year high of $10.95. The stock’s 50-day moving average price is $8.35 and its 200-day moving average price is $8.46.
Achillion Pharmaceuticals (NASDAQ:ACHN) last released its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.01. During the same quarter last year, the company earned ($0.25) earnings per share. On average, equities analysts expect that Achillion Pharmaceuticals Inc. will post ($0.61) earnings per share for the current fiscal year.
A number of research firms have recently commented on ACHN. Leerink Swann reaffirmed a “hold” rating on shares of Achillion Pharmaceuticals in a report on Sunday, June 12th. Zacks Investment Research raised shares of Achillion Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $9.25 price objective for the company in a report on Tuesday. Chardan Capital raised their price objective on shares of Achillion Pharmaceuticals from $4.00 to $5.00 and gave the stock a “sell” rating in a report on Friday, September 23rd. Jefferies Group reaffirmed a “hold” rating on shares of Achillion Pharmaceuticals in a report on Monday, September 26th. Finally, FBR & Co began coverage on shares of Achillion Pharmaceuticals in a report on Thursday, September 15th. They set an “outperform” rating and a $16.00 price target for the company. One research analyst has rated the stock with a sell rating, three have given a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Achillion Pharmaceuticals has an average rating of “Buy” and an average price target of $10.73.
Achillion Pharmaceuticals Company Profile
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system.
Want to see what other hedge funds are holding ACHN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Achillion Pharmaceuticals Inc. (NASDAQ:ACHN).
Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.